Unique ID issued by UMIN | UMIN000051030 |
---|---|
Receipt number | R000058158 |
Scientific Title | The effects of peptide on fatigue decreasing after exercise loading: A randomized, double-blind, placebo-controlled, crossover study |
Date of disclosure of the study information | 2023/05/12 |
Last modified on | 2024/05/09 12:37:48 |
The effects of peptide on fatigue decreasing after exercise loading: A randomized, double-blind, placebo-controlled, crossover study
The effects of peptide on fatigue decreasing after exercise loading: A randomized, double-blind, placebo-controlled, crossover study
The effects of peptide on fatigue decreasing after exercise loading: A randomized, double-blind, placebo-controlled, crossover study
The effects of peptide on fatigue decreasing after exercise loading: A randomized, double-blind, placebo-controlled, crossover study
Japan |
None
Not applicable |
Others
NO
To evaluate the efficacy of peptide on fatigue after exercise loading.
Efficacy
Subjective fatigue (Visual Analog Scale)
1.Blood lactate concentration
2.Subjective fatigue for three days after the exercise day (Visual Analog Scale)
3.Subjective exercise intensity (Borg Scale)
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
3
Prevention
Food |
Single intake of test food(high dose)
Single intake of test food(low dose)
Single intake of placebo food
18 | years-old | <= |
65 | years-old | > |
Male
Subjects aged 18-64 years
1) Subjects who are under treatment or have a history of disorders such as cardiovascular, respiratory, or metabolic system.
2) Subjects who receive a drug treatment or physical therapy.
3) Subjects who have drug allergies or food allergies.
4) Subjects who regularly use food for specified health uses, functional foods, health foods whose affects this study.
5) Subjects who have smoking habit.
6) Subjects whose BMIs are >=30.
7) Subjects drink alcohol polydipsia (pure alcohol equivalent more than 60 g/day)
8) Subjects who participated in clinical trials of other drugs or foods within one month, or who plan to do just after giving informed consent.
9) Subjects who have been ordered not to do exercise by a medical doctor within a year.
10) Subjects who have not taken a medical examination within a year
11) Subjects who are judged inappropriate to this trial by the investigators.
30
1st name | Miyuki |
Middle name | |
Last name | Tanaka |
Morinaga Milk Industry Co., Ltd.
Innovative Research Institute, R&D Division
252-8583
5-1-83,Higashihara,Zama city, Kanagawa, Japan
046-252-3051
kiso-hcrsmng@morinagamilk.co.jp
1st name | Hiroshi |
Middle name | |
Last name | Yoshitake |
Yamaguchi Health Lab.
General manager
754-0041
Medifit Lab 3F, 1-1-2, Ogorireiwa, Yamaguchi city, Yamaguchi Pref., Japan
083-976-4095
info@yamaguchi-hl.com
Morinaga Milk Industry Co., Ltd.
Morinaga Milk Industry Co., Ltd.
Profit organization
Japan Conference of Clinical Research
13-23, 1-Chome, Minami Ikebukuro, Toyoshima-ku, Tokyo, Japan
03-6868-7022
jccr-info@jccr.jp
NO
2023 | Year | 05 | Month | 12 | Day |
Unpublished
Completed
2023 | Year | 04 | Month | 05 | Day |
2023 | Year | 04 | Month | 13 | Day |
2023 | Year | 05 | Month | 15 | Day |
2023 | Year | 10 | Month | 30 | Day |
2023 | Year | 05 | Month | 10 | Day |
2024 | Year | 05 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058158